Nasal Polyposis Therapies
Nasal Polyposis Market


Nasal Polyposis 


Nasal polyposis is small, benign (noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections.


Nasal Polyposis Epidemiology Segmentation in the 7MM


  • Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of Nasal Polyposis
  • Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis


Nasal Polyposis Epidemiological Insights Observed in the 7MM (2021)


  • The total diagnosed prevalent cases of Nasal Polyposis in the 7MM were found to be 4.3 million in the year 2021.
  • The total diagnosed prevalent cases of Nasal Polyposis in the US were observed to be 2.1 million in the year 2021.
  • The total diagnosed prevalent cases of Nasal Polyposis in EU5 were estimated to be 1.9 million, and in Germany were found to be 617k in the year 2021, while they were found to be 435k in UK, and in Spain, they were observed to be 187k cases.
  • The total diagnosed prevalent cases of Nasal Polyposis in Japan were estimated to be 202k cases in 2021.


Nasal Polyposis Market Insight


The market size of Nasal Polyposis in the 7MM was found to be USD 1,532 million in 2021.  


Nasal Polyposis Market Drivers


  • Approval of pipeline drugs in the forecasted period
  • Rising prevalence
  • Increased approvals from regulatory bodies
  • Global exposure


Nasal Polyposis Market Barriers


  • Misdiagnosis
  • Tools to define disease severity not defined well
  • Lack of cost-effective treatment
  • Lack of robust clinical pipeline
  • Limited awareness of nasal polyps


Nasal Polyposis Emerging Therapies


The emerging drugs in the Nasal Polyposis market are

  • Fasenra (benralizumab)
  • Tezepelumab
  • CBP-201
  • PF-06817024, and several others


Nasal Polyposis Key Players 


The key players working in the Nasal Polyposis market are


  • AstraZeneca
  • Amgen
  • Connect Biopharma
  • Pfizer, and others